Eagle Pharmaceuticals(OTC) EGRX

Market Cap$4.81M

Since IPO (2014)-97%

5 Year-99%

1 Year-90%

1 Month-45%

$0.37

-15.91%

-0.07Today

Eagle Pharmaceuticals last closing stock price
Metric	Price	Date
Last close	USD 0.37	2026-07-31

Eagle Pharmaceuticals stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+0%	USD 0.37	2026-07-23
1 month	-44.78%	USD 0.67	2026-07-01
3 month	-22.11%	USD 0.48	2026-04-30
Year to date	-47.14%	USD 0.70	2025-12-31
1 year	-89.97%	USD 3.69	2025-07-31
3 year	-98.24%	USD 21.02	2023-08-01
5 year	-99.2%	USD 46.50	2021-07-30
Since inception	-97.12%	USD 12.83	2014-02-12

Eagle Pharmaceuticals Financials at a Glance

Market Cap

$4.81M

Revenue (TTM)

$257.55M

Net Income (TTM)

$15.57M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-20.44 (Low)

Dividend

$0.00

Beta (Volatility)

-20.44 (Low)

Price

$0.37

Volume

Open

$0.09

Price

$0.37

Volume

Open

$0.09

Previous Close

$0.37

Daily Range

$0.09 - $0.60

52-Week Range

$0.00 - $3.73

Estimated Earnings Date

Aug 11, 2026

Dividend

$0.00

Beta (Volatility)

-20.44 (Low)

Price

$0.37

Volume

Open

$0.09

Previous Close

$0.37

Daily Range

$0.09 - $0.60

52-Week Range

$0.00 - $3.73

Estimated Earnings Date

Aug 11, 2026

EGRX News

Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing innovative product candidates for critical care, oncology, and central nervous system diseases. The company is headquartered in Woodcliff Lake, New Jersey, and has a diverse portfolio of products aimed at addressing significant medical needs.

Products and Services

RYANODEX for malignant hyperthermia
BELRAPZO and BENDEKA for chronic lymphocytic leukemia
PEMFEXY, a ready-to-dilute liquid form of pemetrexed injection

Growth Outlook

Recent quarterly revenue of $64.6 million indicates strong market demand
Strategic collaborations with Tyme Technologies and Combioxin enhance product pipeline
Focus on oncology and critical care markets expected to drive future growth

Financial Highlights

Net income of $5.16 million for Q2 2023, reflecting operational efficiency
Gross profit margin of 73.9% in Q2 2023 demonstrates strong pricing power
Current ratio of 1.70 indicates solid liquidity position

Eagle Pharmaceuticals, Inc. has established itself as a key player in the specialty pharmaceutical sector, with a focus on innovative therapies that address unmet medical needs. The company's recent financial performance showcases its ability to generate significant revenue and maintain a healthy gross profit margin. With a robust product pipeline and strategic partnerships, Eagle Pharmaceuticals is well-positioned for future growth in the competitive healthcare landscape. The company's commitment to developing effective treatments for critical conditions underscores its potential for long-term success.

AI Generated • Jul 26, 2026

Industry

Biotechnology

Sector

Health Care

Employees

135

CEO

Scott L. Tarriff, MBA

Website

www.eagleus.com

Headquarters

Woodcliff Lake, NJ 07677, US

EGRX Financials

Key Financial Metrics (TTM)

Gross Margin

70.01%

Operating Margin

25.57%

Net Income Margin

11.26%

Return on Equity

17.39%

Return on Capital

26.87%

Return on Assets

8.78%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$4.81M

Shares Outstanding

12.99M

Volume

Avg. Volume

6.00K

Financials (TTM)

Gross Profit

$179.88M

Operating Income

$23.65M

EBITDA

$56.98M

Operating Cash Flow

-$9.32M

Capital Expenditure

-$74.00K

Free Cash Flow

-$9.39M

Cash & ST Invst.

$15.35M

Total Debt

$71.62M

Eagle Pharmaceuticals Performance Analysis

Eagle Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2021	2021-12-31	USD 171,546,000	N/A
2022	2022-12-31	USD 316,610,000	84.6%

Eagle Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2022-09-30	-11.1%
Q4	2022-12-31	-7.9%
Q1	2023-03-31	9.2%
Q2	2023-06-30	-2.5%

Eagle Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2021	2021-12-31	USD -0.66	N/A
2022	2022-12-31	USD 2.73	N/A

Eagle Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2022-09-30	63.5%
Q4	2022-12-31	329.6%
Q1	2023-03-31	-29.0%
Q2	2023-06-30	-11.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2023YOY CHG

Revenue

$64.65M

-12.8%

Gross Profit

$47.79M

-5.3%

Gross Margin

73.92%

N/A

Market Cap

$4.81M

N/A

Market Cap/Employee

$34.08K

N/A

Employees

141

N/A

Net Income

$5.16M

+154.6%

EBITDA

$16.33M

+641.1%

Quarterly Fundamentals

Name

Q2 2023YOY CHG

Total Cash

$15.35M

-58.0%

Total Debt

$71.62M

+33.6%

Accounts Receivable

$116.28M

+33.0%

Inventory

$42.48M

-26.4%

Long Term Debt

$62.74M

+107.2%

Short Term Debt

$9.72M

-58.3%

Return on Assets

8.78%

N/A

Return on Invested Capital

27.44%

N/A

Free Cash Flow

-$132.00K

-100.3%

Operating Cash Flow

-$126.00K

-100.3%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

OILFFNextleaf Solutions Ltd.

OILFFNextleaf Solutions Ltd.$0.03+25.20%

ECGSEco-Growth Strategies Inc.

ECGSEco-Growth Strategies Inc.$0.06-24.14%

BLMHBlum Holdings, Inc.

BLMHBlum Holdings, Inc.$0.17-15.58%

UNVCUnivec, Inc.

UNVCUnivec, Inc.$0.00+3.13%

MCUJFMedicure Inc.

MCUJFMedicure Inc.$0.88+19.28%

TRUFFRed Light Holland Corp.

TRUFFRed Light Holland Corp.$0.02+1.36%

CNFHFCanaFarma Hemp Products Corp.

CNFHFCanaFarma Hemp Products Corp.$0.00+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$41.43-0.05%

NVDANvidia

NVDANvidia$206.64+0.03%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.81+0.07%

INTCIntel

INTCIntel$91.00+0.01%

AMZNAmazon

AMZNAmazon$284.02+0.05%

SNAPSnap

SNAPSnap$5.04+0.07%

SOFISoFi Technologies

SOFISoFi Technologies$18.03+0.11%

Questions About EGRX

What is the current price of Eagle Pharmaceuticals?

Eagle Pharmaceuticals is trading at $0.37 per share.

What is the 52-week range for Eagle Pharmaceuticals?

Over the past 52 weeks, Eagle Pharmaceuticals has traded between $0.00 and $3.73.

How much debt does Eagle Pharmaceuticals have?

As of the most recent reporting period, Eagle Pharmaceuticals reported total debt of $65.51M.

How much cash does Eagle Pharmaceuticals have on hand?

Eagle Pharmaceuticals reported $55.32M in cash and cash equivalents in its most recent financial results.

What is Eagle Pharmaceuticals’s dividend yield?

Eagle Pharmaceuticals does not currently have a dividend yield.

Eagle Pharmaceuticals(OTC) EGRX

Eagle Pharmaceuticals Financials at a Glance

EGRX News

3 Stocks the Smartest Investors Are Buying Right Now

3 Top Biotech Stocks to Buy in 2017

Why Eagle Pharmaceuticals, Inc. Is Soaring 21.6% Today

Why Eagle Pharmaceuticals Inc. Flew 38.5% Higher in August

Why Eagle Pharmaceuticals, Inc. Skyrocketed 27.8% Today

Here's Why Eagle Pharmaceuticals' Stock Cratered Today

The Best Biotech Stocks in 2015

3 Moneymaking Biotech Stocks to Consider Buying

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Eagle Pharmaceuticals

EGRX Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Eagle Pharmaceuticals Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About EGRX

What is the current price of Eagle Pharmaceuticals?

What is the 52-week range for Eagle Pharmaceuticals?

How much debt does Eagle Pharmaceuticals have?

How much cash does Eagle Pharmaceuticals have on hand?

What is Eagle Pharmaceuticals’s dividend yield?

Premium Investing Services